EMA backs cattle vaccine against lumpy skin disease

The European Medicines Agency has recommended granting EU-wide marketing authorisation for a vaccine targeting lumpy skin disease, a viral infection affecting cattle. The Amsterdam-based regulator's scientific recommendation clears the primary technical hurdle required for the preventative treatment to be approved across the 27-nation single market.

For livestock farmers, contagious animal diseases bring the double threat of compromised herd health and immediate trade restrictions. Lumpy skin disease damages hides, cuts milk production, and frequently triggers movement curbs on livestock. Having an authorised vaccine provides farmers and veterinary authorities with an approved defence against potential cross-border outbreaks without having to resort solely to herd culls.

Under the European Union's regulatory machinery, the medicines agency is tasked with evaluating clinical safety and quality but holds no authority to issue the licence itself. Instead, it delivers a scientific opinion to the European Commission, which holds the executive pen. The Commission almost invariably ratifies the agency's green light, maintaining a polite division between scientific assessment in the laboratory and executive decree in Brussels.

The dossier heads to the European Commission to be formally translated into a binding marketing authorisation. Once that formal decision is adopted, member states will be able to incorporate the vaccine into their national animal health programmes.